Abstract:The Tousled like kinases 1 and 2 (TLK1 and TLK2) are evolutionarily conserved Ser/Thr kinases that are required for genome stability and normal development in numerous organisms. Both kinases contribute to histone deposition by targeting the histone chaperones ASF1A and ASF1B and are regulated by the DNA damage response (DDR). TLK1/2 expression is ubiquitous and often elevated in human cancers with suppressed immune gene expression. In some cancer types, elevated TLK levels correlate with decreased disease-free survival. In cultured cells, TLK depletion causes replication stress, DNA damage and altered chromatin maintenance. TLK1/2 depletion increases the efficacy of DNA damage checkpoint inhibitors and PARP inhibitors and induces the Alternative-lengthening of telomeres pathway and innate immune signaling. Collectively, this data suggests that TLK activity may be a druggable anti-cancer target. To test this, we generated a conditional Tlk2 allele in mice and introduced the Mouse Mammary Tumor Virus-Polyoma Middle Tumor-antigen (MMTV-PyMT) transgene to generate breast cancers. Deletion of Tlk2 in developing breast cancer resulted in impaired primary tumor growth and a complete inhibition of lung metastasis. Characterization of the tumor microenvironment revealed elevated immune infiltration that includes activated T cells with higher levels of PD-1, which could potentially sensitize these tumors to immune checkpoint blockade. To test this possibility, we established a syngeneic breast cancer model to allow us to combine Tlk2 depletion or deletion with DDR inhibitor and anti-PD-1 therapy in vivo. Preliminary data supports the strategy of targeting Tlk2 in cancer and we will share current data from tumor models and preliminary characterization of small molecule inhibitors. Citation Format: Marina Villamor-Payá, Adrià Caballé, Jordann Smak, Mohamed-Reda Benmebarek, Camille Stephan-Otto Attolini, Travis H. Stracker. Targeting Tlk2 impairs breast cancer growth and engages immune responses [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Damage Repair: From Basic Science to Future Clinical Application; 2024 Jan 9-11; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2024;84(1 Suppl) nr A017.

A Novel Screen for Expression Regulators of the Telomeric Protein TRF2 Identified Small Molecules That Impair TRF2 Dependent Immunosuppression and Tumor Growth

TRAF2 Inhibits Senescence in Hepatocellular Carcinoma Cells Via Regulating the ROMO1/ NAD+/SIRT3/SOD2 Axis.

TRF2 Inhibits a Cell-Extrinsic Pathway Through Which Natural Killer Cells Eliminate Cancer Cells

Growth Inhibition and Radiosensitization of Glioblastoma and Lung Cancer Cells by Small Interfering RNA Silencing of Tumor Necrosis Factor Receptor–Associated Factor 2

Molecular Targeting of TRF2 Suppresses the Growth and Tumorigenesis of Glioblastoma Stem Cells.

Development and Optimization of a Cascade of Screening Assays for Inhibitors of TRF2.

Multiple cancer pathways regulate telomere protection

Expression of Telomeric Repeat Binding Factor 1 in Non-Small Cell Lung Cancer.

Knockdown of telomeric repeat binding factor 2 enhances tumor radiosensitivity regardless of telomerase status

Trf2 Promotes Multidrug Resistance In Gastric Cancer Cells

Drug-repurposing screen identifies thiostrepton as a novel regulator of the tumor suppressor DAB2IP

Sp1 upregulates expression of TRF2 and TRF2 inhibition reduces tumorigenesis in human colorectal carcinoma cells.

Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth

Targeting BRF2: insights from in silico screening and molecular dynamic simulations

Ribosomal Biogenesis Hyperactivation and ErbB signalling Mediated Network Rewiring Causes Adaptive Resistance to FGFR2 Inhibition

Inhibition of TRF2 Leads to Ferroptosis, Autophagic Death, and Apoptosis by Causing Telomere Dysfunction

Knockdown of TNF Receptor-Associated Factor 2 (TRAF2) Modulates in Vitro Growth of TRAIL-treated Prostate Cancer Cells.

Telomere Protection and TRF2 Expression Are Enhanced by the Canonical Wnt Signalling Pathway

Abstract A017: Targeting Tlk2 impairs breast cancer growth and engages immune responses

The Topoisomerase II Catalytic Inhibitor ICRF-193 Preferentially Targets Telomeres That Are Capped by TRF2.

High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro